e-Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2021

Rate of patients receiving second-line treatment for metastatic colorectal cancer in a real-world setting (#209)

Katherine Ups 1 , Alessandra Francesconi 2 , Elizabeth G Ryan 3 4
  1. Griffith Univeristy, Sunshine Coast, QLD
  2. Sunshine Coast Hospital and Health Service, Sunshine Coast, QLD
  3. Centre for Health Services Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD
  4. QCIF Facility for Advanced Bioinformatics, Institute for Molecular Bioscience, The University of Queensland, Brisbane

Background:

Colorectal cancer is the third most common cancer diagnosed in Australia. Although a large portion (46.4%) present at an early stage, up to 45% relapse and many others present with de novo metastatic disease.(1, 2) Although the treatment landscape for metastatic colorectal cancer (mCRC) is rapidly evolving, little is known about real-world impact of various regimens or utilisation rates of treatments beyond first-line.

Aims:

To evaluate the real-world rates of mCRC patients receiving systemic therapy beyond first line at a regional cancer centre (Sunshine Coast Hospital and Health Service - SCHHS). As well as the regimen choice and relative rates of treatment progression of the different regimens utilised in the first-line.

Methods:

A retrospective analysis of all patients with mCRC who received first-line palliative systemic chemotherapy between January 2014 and December 2020 at SCHHS has been conducted. Real-world treatment patterns including rates of progression and survival were also examined.

Results:

During this time period, 249 patients diagnosed with mCRC received first-line treatment at our center. Of these patients, 136 (54.6%) patients progressed to second-line treatment. Progression rates dropped through treatment lines, with 18.9% and 5.2% of patients receiving 3rdand 4thline treatments respectively. Doublet therapy with or without a biological agent was the most commonly used first line treatment option with 199 patients (79.9%).

Conclusion:

54.6% of mCRC patients at our center progressed onto second line treatment therapy, which is higher than the current literature with studies reporting rates of 48.9% and 52.2%. (3, 4)These results show that at our center, although percentages are lower than initially perceived, they are higher than other international statistics.

 

  1. 1. Welfare AIoHa. Cancer in Australia 2019. Canberra: AIHW; 2019.
  2. 2. Wilhelmsen M, Kring T, Jorgensen LN, Madsen MR, Jess P, Bulut O, et al. Determinants of recurrence after intended curative resection for colorectal cancer. Scand J Gastroenterol. 2014;49(12):1399-408.
  3. 3. Hess LM, Cui ZL, Mytelka DS, Han Y, Goodloe R, Schelman W. Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA. Int J Colorectal Dis. 2019;34(4):581-8.
  4. 4. Jeremy Snider EWSAJSGSWCRFVS, Scott David R. Metastatic colorectal cancer (mCRC) treatment patterns in the the Medicare population. Journal of Clinical Oncology. 2018;36(4):823-.